StockNews.AI
COEP
StockNews.AI
194 days

COEPTIS Completes $10 Million Series A Preferred Financing Round, Reinforcing Commitment to Technological Innovation and AI Integration

1. COEPTIS raises $5.7 million, total financing reaches $10 million. 2. Funding led by CJC Investment Trust, enhancing investor confidence. 3. Capital supports AI integration and operational growth in biotech sector. 4. New Technology Division focuses on AI and automation for efficiency. 5. Company aims for innovation in therapies amid evolving healthcare landscape.

9m saved
Insight
Article

FAQ

Why Bullish?

Strong investor backing signifies confidence, reminiscent of biotech funding trends boosting shares.

How important is it?

The financing closure highlights growth potential, crucial for COEP's strategic shift towards tech integration.

Why Long Term?

Investment in technology and AI could yield sustained growth and innovation, as seen in other biotech firms.

Related Companies

CJC Investment TrustDeverra Therapeutics
WEXFORD, Pa., Feb. 6, 2025 /PRNewswire/ -- COEPTIS, Inc. (Nasdaq: COEP) (the "Company" or "Coeptis"), a pioneering technology company dedicated to advancing cutting-edge technologies and artificial intelligence at the forefront of innovative biotechnology therapeutic solutions, today announced the successful closure of an additional $5.7 million in its final Series A Preferred Offering, bringing the total financing round to $10 million. This significant achievement highlights investor confidence in Coeptis' innovative therapeutic solutions and its strategic pivot towards technology-driven growth. The financing was led by CJC Investment Trust, an entity controlled by board member Christopher Calise, through an increase in their initial investment in the round. Under the terms of the latest financing, the Series A Preferred is convertible into shares of the Company's common stock at a price of $8.00 per share, subject to limitations. Additionally, investors received an aggregate 15% equity interest in the Company's newly formed subsidiaries, SNAP Biosciences Inc. and GEAR Therapeutics Inc. This announcement follows an initial closure of $4.3 million in June 2024. "We're thrilled to announce the successful closure of our second Series A Preferred financing," said Brian Cogley, CFO of COEPTIS. "This funding is pivotal as we expand our operational capabilities and enhance shareholder value through our new Technology Division. The integration of AI-driven tools, particularly from our recent acquisition of the NexGenAI Affiliates Network platform, is vital in revolutionizing our approach to marketing and operational efficiencies in the highly regulated biopharmaceutical sector." The proceeds from this financing will be utilized to strengthen the Company's balance sheet, repay outstanding obligations, and support general corporate purposes, alongside the $4.3 million already raised. Moreover, the additional capital will accelerate Coeptis' ongoing integration of advanced AI solutions and automation capabilities, enhancing not only research processes but also the overall operational framework of the Company. "This additional financing enables Coeptis to not just fortify its mission in cell therapy but also empowers us to drive innovation in technology and AI," added Dave Mehalick, President and CEO of COEPTIS. "By fostering a culture of responsible innovation, we aim to capitalize on diverse growth opportunities, creating a self-sustaining business model that establishes a strong foundation for long-term success and profitability." About COEPTIS, Inc. COEPTIS, Inc., together with its subsidiaries Coeptis Pharmaceuticals, Inc., GEAR Therapeutics, Inc., and SNAP Biosciences, Inc. (collectively "Coeptis"), is a biopharmaceutical and technology company focused on developing innovative cell therapy platforms for cancer, autoimmune, and infectious diseases. Coeptis aims to advance treatment paradigms and improve patient outcomes through its cutting-edge research and development efforts. The Company's therapeutic portfolio is underscored by assets licensed from Deverra Therapeutics, which include an allogeneic cellular immunotherapy platform and DVX201, a clinical-stage, unmodified natural killer cell therapy technology. COEPTIS is also developing a universal, multi-antigen CAR technology licensed from the University of Pittsburgh (SNAP-CAR), alongside GEAR cell therapy and companion diagnostic platforms in collaboration with VyGen-Bio and distinguished medical researchers at the Karolinska Institute. Building on its core competencies, COEPTIS has recently established a Technology Division, which focuses on enhancing operational capabilities through advanced technologies. This division features AI-powered marketing software and robotic process automation tools acquired from NexGenAI Solutions Group, designed to optimize business processes and improve overall efficiency. Headquartered in Wexford, PA, COEPTIS is dedicated to advancing its mission within the regulatory framework set forth by the FDA, ensuring that all activities align with the highest standards of compliance and patient care. For more information on COEPTIS, visit https://coeptistx.com Cautionary Note Regarding Forward-Looking Statements This press release and statements of our management made in connection therewith contain or may contain "forward-looking statements" (as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended). Forward-looking statements include statements concerning our plans, objectives, goals, strategies, future events or performance, and underlying assumptions, and other statements that are other than statements of historical facts. When we use words such as "may," "will," "intend," "should," "believe," "expect," "anticipate," "project," "estimate" or similar expressions that do not relate solely to historical matters, we are making forward-looking statements. Forward-looking statements are not a guarantee of future performance and involve significant risks and uncertainties that may cause the actual results to differ materially and perhaps substantially from our expectations discussed in the forward-looking statements. Factors that may cause such differences include but are not limited to: (1) the inability to maintain the listing of the Company's securities on the Nasdaq Capital Market; (2) the inability to recognize the anticipated benefits of the Deverra licensed assets, which may be affected by, among other things, competition, the ability of the Company to grow and manage growth economically and hire and retain key employees; (3) the risks that the Company's products in development or the newly-licensed assets fail clinical trials or are not approved by the U.S. Food and Drug Administration or other applicable regulatory authorities; (4) costs related to ongoing asset development including the Deverra licensed assets and pursuing the contemplated asset development paths; (5) changes in applicable laws or regulations; (6) the possibility that the Company may be adversely affected by other economic, business, and/or competitive factors; and (7) the impact of the global COVID-19 pandemic on any of the foregoing risks and other risks and uncertainties identified in the Company's filings with the Securities and Exchange Commission (the "SEC"). The foregoing list of factors is not exclusive. All forward-looking statements are subject to significant uncertainties and risks including, but not limited, to those risks contained or to be contained in reports and other filings filed by the Company with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company's filings made or to be made with the SEC, which are available for review at www.sec.gov. We undertake no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof unless required by applicable laws, regulations, or rules. Contacts[email protected] SOURCE Coeptis Pharmaceuticals, Inc.

Related News